What is MRK stock price today?

MRK (Merck & Co Inc) stock is trading at $120.13 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is MRK stock going up or down today?

MRK stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy MRK stock now?

The decision to buy MRK depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is MRK a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for MRK based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is MRK stock overvalued or undervalued?

MRK currently trades at a P/E ratio of 16.66 relative to earnings. Our DCF calculator provides intrinsic value estimates to help determine if MRK is fairly priced.

What is MRK's P/E ratio?

MRK has a price-to-earnings (P/E) ratio of 16.66, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is MRK's market cap?

MRK (Merck & Co Inc) has a market capitalization of $300.20 billion, making it a large-cap stock.

What is MRK's price to book ratio?

MRK trades at a price-to-book (P/B) ratio of 5.70, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does MRK pay dividends?

Yes, MRK pays dividends with a current yield of 0.03%. Dividend payments provide income for investors in addition to potential stock price appreciation.

What is MRK's dividend yield?

MRK's dividend yield is 0.03%, calculated as annual dividends divided by the current stock price. This represents the annual return from dividends alone.

Is MRK stock a good long-term investment?

MRK's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is MRK's revenue growth rate?

MRK has shown revenue growth of 0.1% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, MRK is profitable with a profit margin of 0.3%. This indicates the company generates 0.3 cents of profit for every dollar of revenue.

What are the risks of investing in MRK?

Key risks for MRK include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does MRK compare to its competitors?

Compare MRK to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize MRK's performance and positioning.

What is MRK's stock price target for 2026?

Our AI model provides price targets for MRK based on fundamental analysis: Bull case $156.16 (+30%), Base case $138.14 (+15%), Bear case $108.11 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about MRK?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for MRK. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is MRK's next earnings report?

MRK reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

MRK - Merck & Co Inc

NYSE * Health Care * Pharmaceuticals

$120.13

$-1.29 (-1.07%)

About Merck & Co Inc

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

MRK Key Statistics

Market Cap

$300.20B

P/E Ratio

16.66

P/B Ratio

5.70

EPS

$7.29

Dividend Yield

0.03%

Revenue Growth

+0.1%

Profit Margin

0.3%

Employees

73,000

How MRK Compares to Peers

MRK has the lowest P/E ratio in Pharmaceuticals, suggesting it may be the most undervalued

MRK has the highest profit margins in Pharmaceuticals

MRK is the smallest among peers, which may offer higher growth potential

P/E Rank

of 2

Margin Rank

of 2

Growth Rank

of 2

Size Rank

of 2

Company	Market Cap	P/E	Growth	Margin	Compare
MRK(This stock)	$300.20B	16.7	0%	0.3%	-
AMZNAmazon Com	$2.56T	33.2	0%	0.1%	vs AMZN

Merck & Co Inc Company Information

Headquarters: New Jersey; U.S.A
Website: www.merck.com
Sector: Health Care
Industry: Pharmaceuticals

MRK - Merck & Co Inc

About Merck & Co Inc

MRK Key Statistics

How MRK Compares to Peers

Merck & Co Inc Company Information

MRK Lician Score

MRK Financial Snowflake

Upcoming Events for MRK